Swiss National Bank
CYCN icon

Swiss National Bank’s Cyclerion Therapeutics CYCN Stock Holding History

Swiss National Bank’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,412
Closed -$75K – 2458
2020
Q1 		$75K Hold
1,412
– – ﹤0.01% 2476
2019
Q4 		$77K Hold
1,412
– – ﹤0.01% 2506
2019
Q3 		$342K Buy
1,412
+135
+11% +$29.2K ﹤0.01% 2438
2019
Q2 		$292K Buy
+1,277
New +$361K ﹤0.01% 2518

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Swiss National Bank's CYCN Position: Q2 2020 in Review

Swiss National Bank sold out of Cyclerion Therapeutics (CYCN) in Q2 2020, closing a stake of 1,412 shares — an estimated $75K sold.

Swiss National Bank first reported a position in CYCN in Q2 2019 and held it in 4 quarters. The position peaked at $342K in Q3 2019. 74 funds tracked by Wall St. Rank hold CYCN as of Q2 2020.

  • Swiss National Bank reported no remaining Cyclerion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Swiss National Bank sold 1,412 Cyclerion Therapeutics shares in Q2 2020, an estimated $75K.
  • Swiss National Bank first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 4 quarters.
  • Swiss National Bank's Cyclerion Therapeutics position peaked at $342K in Q3 2019.
  • 74 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2020.

Based on Swiss National Bank's 13F filing for Q2 2020, filed 5 Aug 2020.